Shorter, more effective treatments for tuberculosis
Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium
['FUNDING_OTHER'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11374861
Developing and prioritizing drug combinations to create shorter, more effective treatments for people with tuberculosis.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11374861 on ClinicalTrials.gov |
What this research studies
A team of researchers and drug developers is combining lab experiments, animal studies, and computer-based pharmacometric modeling to predict which multi-drug regimens are most likely to cure TB faster. They will standardize preclinical experiments across sites and use modeling to rank combinations before moving into expensive human trials. The consortium also aims to find early lab or animal markers that reliably predict which regimens will work in people. By coordinating these efforts, they hope to speed up which drug combinations advance to clinical testing.
Who could benefit from this research
Good fit: People with active tuberculosis (including drug-susceptible and drug-resistant TB), including adults and children, who might enroll in future clinical trials of new drug combinations.
Not a fit: People without active TB (for example those with latent TB or who are already cured) are unlikely to directly benefit from this preclinical-focused work.
Why it matters
Potential benefit: If successful, this work could shorten TB treatment courses, reduce side effects, and improve cure rates.
How similar studies have performed: Previous animal-model and modeling approaches have helped shorten some TB regimens to 4–6 months, but this coordinated preclinical-to-translation approach is broader and more systematic than most past efforts.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SAVIC, RADOJKA — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: SAVIC, RADOJKA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.